Last checked at 
(Alliance News) - Allergy Therapeutics PLC on Monday reported positive top-line results from the G309 exploratory field trial to evaluate the efficacy and safety of Grass MATA MPL.
Grass MATA MPL is a short-course subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
Two short courses of six injections with treatment durations of six and 14 weeks were tested.
AIM-listed Allergy Therapeutics shares were trading 14% higher in London on Monday at 38.17 pence each.
The Worthing, England-based pharmaceutical company said the G309 trial was a double-blind, placebo controlled, randomised study over one year and involved 119 patients over 14 sites across Germany and the US.
Allergy Therapeutics highlighted that primary endpoint of combined symptom medication score was achieved with clinically relevant improvement across both active treatment groups compared to placebo.
These results from the trial will be used to optimise the study design of the upcoming pivotal phase III study due to begin in the second half of 2022 in the EU and US, the company said.
"We are delighted to announce these results demonstrating a clear treatment effect from our novel, short-course immunotherapy targeting grass pollen allergies," said Chief Executive Manuel Llobet.
"The results will enable us to optimally design the upcoming pivotal G306 Phase III field trial, maximising the chances of success and supporting our regulatory plans for entry into the US," added Llobet.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
